Ameriprise’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Ameriprise’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-26,438	Closed	-$1.29M	–	3944
2021 Q2	$1.29M	Buy	26,438 +1,098	+4%	+$52.6K	﹤0.01%	3114
2021 Q1	$1.27M	Buy	+25,340	New	+$1.4M	﹤0.01%	3046
2017 Q1	–	Sell	-9,868	Closed	-$226K	–	3667
2016 Q4	$226K	Buy	+9,868	New	+$236K	﹤0.01%	3618

Other funds holding SBIO

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

CCP

Cardan Capital Partners Denver, Colorado $893M AUM 22.82% 1-Year Est. Return

NAM

NTV Asset Management Charleston, West Virginia $910M AUM 27.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Ameriprise's SBIO Position: Q3 2021 in Review

Ameriprise sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q3 2021, closing a stake of 26,438 shares — an estimated $1.29M sold.

Ameriprise first reported a position in SBIO in Q4 2016 and held it in 3 quarters. The position peaked at $1.29M in Q2 2021. 60 funds tracked by Wall St. Rank hold SBIO as of Q3 2021.

Ameriprise reported no remaining ALPS Medical Breakthroughs ETF position as of Q3 2021 after selling out during the quarter.
Ameriprise sold 26,438 ALPS Medical Breakthroughs ETF shares in Q3 2021, an estimated $1.29M.
Ameriprise first reported a position in ALPS Medical Breakthroughs ETF in Q4 2016 and held it in 3 quarters.
Ameriprise's ALPS Medical Breakthroughs ETF position peaked at $1.29M in Q2 2021.
60 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q3 2021.

Based on Ameriprise's 13F filing for Q3 2021, filed 15 Nov 2021.